Taysha Gene Therapies
TSHA | NASDAQ
$4.06
-$0.04 (-0.98%)
At close: Nov 16, 2026, 4:00 PM ET
$4.06
$0.00 (0.00%)
After-hours:
Nov 16, 2026, 4:10 PM ET
Taysha Gene Therapies Company Profile
Company profile explainedCompany Profile
Taysha Gene Therapies, Inc. is a biotech firm specializing in the creation and market introduction of gene therapies that utilize adeno-associated virus (AAV) vectors. Its core mission is to tackle inherited diseases affecting the central nervous system (CNS). The company's development pipeline features several key programs: TSHA-120 is aimed at giant axonal neuropathy; TSHA-102 is in development for Rett syndrome; TSHA-121 and TSHA-118 are both being advanced for CLN1 disease; TSHA-105 addresses SLC13A5 Deficiency; and TSHA-101 targets GM2 gangliosidosis. Furthermore, Taysha has forged a strategic alliance with The University of Texas Southwestern Medical Center to jointly advance and bring to market innovative gene therapy solutions. Founded in 2019, the company operates from its headquarters in Dallas, Texas.
Key Executives
| Name | Position |
|---|---|
| Sean Nolan | Chief Executive Officer & Chairman |
| Kamran Alam | Chief Financial Officer & Corporate Secretary |
| Michael Johannesen | Chief Legal Officer & Corporate Secretary |
| Berge Minassian | Chief Medical Advisor of UT Southwestern Gene Therapy Program |
| Emily McGinnis | Chief Patient & External Affairs Officer |
| Frederick Porter | Chief of Staff & Technical Operations Officer |
| Hayleigh Collins | Director of Corporate Communications & Investor Relations |
| Sean McAuliffe | Chief Business Officer |
| Steven Gray | Chief Scientific Advisor of UT Southwestern Gene Therapy Program |
| Sukumar Nagendran | President, Head of Research & Development and Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 14, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Aug 13, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Aug 11, 2026 | 10-Q | Quarterly Report |
| Aug 11, 2026 | 8-K | Current Report |
| Jul 10, 2026 | 4 | Filing |
| Jun 25, 2026 | 8-K | Current Report |
| Jun 25, 2026 | 424B5 | Filing |
| Jun 24, 2026 | 424B5 | Filing |
| Jun 22, 2026 | 8-K | Current Report |
| Jun 02, 2026 | 4 | Filing |
Taysha Gene Therapies
| Country | United States |
| IPO Date | Sep 24, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 99 |
| CEO | Sean Nolan |
Contact Details
3000 Pegasus Park Drive Dallas,
Texas 75247 United States
Stock Details
| Ticker Symbol | TSHA |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001806310 |
| CUSIP Number | 877619106 |
| ISIN Number | US8776191061 |
| SIC Code | 2836 |
Recent News
- 4 days ago / seekingalpha.comTaysha Gene Therapies, Inc. (TSHA) Q3 2026 Earnings Call Transcript
- 4 days ago / marketbeat.comTaysha Gene Therapies Q3 Earnings Call Highlights
- 4 days ago / globenewswire.comTaysha Gene Therapies Reports Third Quarter 2026 Financial Results and Provides Corporate Update
- 12 days ago / globenewswire.comTaysha Gene Therapies to Release Third Quarter 2026 Financial Results and Host Conference Call and Webcast on November 12
- 2 months ago / globenewswire.comTaysha Gene Therapies Announces Multiple Encore Presentations Supporting TSHA-102 Rett Syndrome Clinical Program at the 55th Child Neurology Society Annual Meeting
- 2 months ago / seekingalpha.comTaysha Gene Therapies: A Bull Case That Does Not Require The Fastest Approval
- 3 months ago / seekingalpha.comTaysha Gene Therapies, Inc. (TSHA) Q2 2026 Earnings Call Transcript
- 3 months ago / marketbeat.comTaysha Gene Therapies Q2 Earnings Call Highlights
- 3 months ago / globenewswire.comTaysha Gene Therapies Reports Second Quarter 2026 Financial Results and Provides Corporate Update
- 5 months ago / seekingalpha.comTaysha: 'Buy' On Interim Analysis Of TSHA-102 First Half 2027 And Broad Label Potential
Add to Watchlist
Select watchlists to add or remove TSHA